Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of “Hold” from Analysts
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have earned an average recommendation of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $22.81.
Several research firms have recently issued reports on OCUL. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. BTIG Research reaffirmed a “neutral” rating on shares of Ocular Therapeutix in a research report on Monday, July 17th. HC Wainwright set a $10.00 price objective on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price objective on shares of Ocular Therapeutix in a research report on Monday, May 15th. Finally, Zacks Investment Research cut shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd.
Shares of Ocular Therapeutix (NASDAQ OCUL) opened at 6.04 on Tuesday. Ocular Therapeutix has a one year low of $4.04 and a one year high of $11.91. The stock’s market cap is $175.33 million. The stock’s 50 day moving average price is $8.37 and its 200 day moving average price is $8.77.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.10. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.51 million. Ocular Therapeutix had a negative return on equity of 80.26% and a negative net margin of 2,620.06%. During the same period last year, the firm posted ($0.35) earnings per share. Analysts forecast that Ocular Therapeutix will post ($2.19) earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix during the first quarter worth $455,000. JPMorgan Chase & Co. bought a new stake in shares of Ocular Therapeutix during the first quarter worth $3,394,000. GWM Advisors LLC bought a new stake in shares of Ocular Therapeutix during the first quarter worth $381,000. NEXT Financial Group Inc bought a new stake in shares of Ocular Therapeutix during the first quarter worth $480,000. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 401 shares during the period. 65.04% of the stock is owned by hedge funds and other institutional investors.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.